EXPERIENCE IN APPLYING THE TECHNOLOGY OF CYTOREDUCTIVE SURGERY WITH HYPERTHERMIC INTRAOPERATIVE INTRAPERITONEAL CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH PERITONEAL CARCINOMATOSIS
https://doi.org/10.21294/1814-4861-2018-17-3-58-63
Abstract
We present our experience in using cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer patients treated at Irkutsk Regional Cancer Center. All patients were divided into 2 groups. Group I consisted of 15 patients, who underwent cytoreductive surgery only. Group II comprised 17 patients, who underwent surgery and HIPEC. The main eligibility criteria for this study were verified peritoneal carcinomatosis and resectable ovarian cancer. The primary analysis of these groups included: preoperative period, length of operation, postoperative length of stay, and postoperative complications. The technique of performing HIPEC using Performer HT® (RAND, Medolla (MO), Italy) was completely described. Further study is required to estimate the difference in overall and disease-free survival between study groups.
About the Authors
A. V. Shelekhov
Regional Cancer Center
Irkutsk State Medical University
Russian Federation
Russian Federation
32, Frunze Street, 664042-Irkutsk, Russia
1, Krasnogo Vosstaniya Street, 664003-Irkutsk, Russia
MD, DSc, Professor, Regional Cancer Center; Irkutsk State Medical University (Irkutsk, Russia)
V. V. Dvornichenko
Regional Cancer Center
Irkutsk State Medical University
Russian Federation
Russian Federation
32, Frunze Street, 664042-Irkutsk, Russia
1, Krasnogo Vosstaniya Street, 664003-Irkutsk, Russia
MD, DSc, Professor, Regional Cancer Center; Irkutsk State Medical University (Irkutsk, Russia)
S. I. Radostev
Regional Cancer Center
Russian Federation
Russian Federation
32, Frunze Street, 664042-Irkutsk, Russia
MD, Physician, Regional Cancer Center (Irkutsk, Russia)
D. D. Morikov
Regional Cancer Center
Russian Federation
Russian Federation
32, Frunze Street, 664042-Irkutsk, Russia
MD, Anesthesiologist, Regional Cancer Center (Irkutsk, Russia)
R. I. Rasulov
Regional Cancer Center
Russian Federation
Russian Federation
32, Frunze Street, 664042-Irkutsk, Russia
MD, DSc, Regional Cancer Center (Irkutsk, Russia)
I. V. Ushakova
Regional Cancer Center
Russian Federation
Russian Federation
32, Frunze Street, 664042-Irkutsk, Russia
MD, PhD, Regional Cancer Center (Irkutsk, Russia)
A. A. Medvednikov
Regional Cancer Center
Russian Federation
Russian Federation
32, Frunze Street, 664042-Irkutsk, Russia
MD, Physician, Regional Cancer Center (Irkutsk, Russia)
A. G. Zaharov
Regional Cancer Center
Russian Federation
Russian Federation
32, Frunze Street, 664042-Irkutsk, Russia
MD, Physician, Regional Cancer Center (Irkutsk, Russian Federation)
R. N. Demonov
Regional Cancer Center
Russian Federation
Russian Federation
32, Frunze Street, 664042-Irkutsk, Russia
MD, Physician, Regional Cancer Center (Irkutsk, Russia)
O. V. Gladkova
Regional Cancer Center
Russian Federation
Russian Federation
32, Frunze Street, 664042-Irkutsk, Russia
MD, Physician, Regional Cancer Center (Irkutsk, Russia).
N. M. Chernorubashkina
Regional Cancer Center
Russian Federation
Russian Federation
32, Frunze Street, 664042-Irkutsk, Russia
MD, Physician, Regional Cancer Center (Irkutsk, Russia)
References
1. Aebi S., Castiglione M.; ESMO Guidelines Working Group. Newly and relapsed epithelial ovarian carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009 May; 20 Suppl 4: 21–3. doi: 10.1093/annonc/mdp117.
2. Practical guidelines on the medicinal treatment of malignant tumors. Malignant tumors. 2017; 7 (3): 135–145. [in Russian]
3. Winter W.E.3rd, Maxwell G.L., Tian C., Carlson J.W., Ozols R.F., Rose P.G., Markman M., Armstrong D.K., Muggia F., McGuire W.P.; Gynecologic Oncology Group Study. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2007; 25: 3621–7.
4. Amanov S.B., Shanazarov N.A., Privalov A.V. The role of hyperthermic intraoperativ intraperitontal chemoperfusion in treatment of malignant neoplasms and abdominal carcinomatosis. Modern Problems of Science and Education. 2013; 6: 661. [in Russian]
5. Savinova A.R., Gataullin I.G. Personalized approach to the ovarian cancer treatment. Kazan Medical Journal. 2016; 97 (3): 388–393. doi: 10.17750/KMJ2016-388. [in Russian]
6. Pokataev I., Kormosh Dr.N., Laktionov K.P., Mihina Z., Kurganova I., Tuliandina A., Tuliandin S. Current treatment options for patients with recurrent ovarian carcinoma. Bulletin of the Moscow Cancer Society. 2014; 1: 3–8. [in Russian]
7. Piso P., Dahlke M-H., Loss M., Schlitt H.J. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J Surg Oncol. 2004; 2: 21. doi: 10.1186/1477-7819-2-21.
8. Draguła J., Konopacki A., Kwaśniewska M., Sokołowski R., Zukow W. The use of surgical cytoreduction in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of cancerous peritonitis in patients with gastric cancer or colon cancer. J Health Sci. 2013; 3 (9): 077–086.
Review
For citations:
Shelekhov A.V., Dvornichenko V.V., Radostev S.I., Morikov D.D., Rasulov R.I., Ushakova I.V., Medvednikov A.A., Zaharov A.G., Demonov R.N., Gladkova O.V., Chernorubashkina N.M. EXPERIENCE IN APPLYING THE TECHNOLOGY OF CYTOREDUCTIVE SURGERY WITH HYPERTHERMIC INTRAOPERATIVE INTRAPERITONEAL CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH PERITONEAL CARCINOMATOSIS. Siberian journal of oncology. 2018;17(3):58-63. (In Russ.) https://doi.org/10.21294/1814-4861-2018-17-3-58-63
Views:
1100
Email this article 
